Jane Street Group LLC reduced its stake in shares of Opko Health Inc. (NASDAQ:OPK) by 22.3% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 263,011 shares of the biotechnology company’s stock after selling 75,560 shares during the period. Jane Street Group LLC’s holdings in Opko Health were worth $1,805,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in the company. Cornerstone Capital Management Holdings LLC. boosted its holdings in Opko Health by 611.8% in the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 1,445,310 shares of the biotechnology company’s stock worth $9,913,000 after buying an additional 1,242,272 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Opko Health by 127.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 4,003,643 shares of the biotechnology company’s stock worth $27,466,000 after buying an additional 2,241,103 shares during the period. Schwab Charles Investment Management Inc. boosted its holdings in Opko Health by 43.0% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 1,566,433 shares of the biotechnology company’s stock worth $10,746,000 after buying an additional 471,256 shares during the period. Wells Fargo & Company MN boosted its holdings in Opko Health by 14.3% in the 3rd quarter. Wells Fargo & Company MN now owns 481,085 shares of the biotechnology company’s stock worth $3,300,000 after buying an additional 60,177 shares during the period. Finally, Legal & General Group Plc boosted its holdings in Opko Health by 17.4% in the 3rd quarter. Legal & General Group Plc now owns 141,535 shares of the biotechnology company’s stock worth $971,000 after buying an additional 21,017 shares during the period. 22.91% of the stock is owned by hedge funds and other institutional investors.

In other Opko Health news, major shareholder Opko Health, Inc. bought 655,738 shares of the firm’s stock in a transaction that occurred on Monday, October 30th. The shares were bought at an average price of $3.05 per share, for a total transaction of $2,000,000.90. Following the transaction, the insider now directly owns 6,678,752 shares in the company, valued at $20,370,193.60. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Phillip Md Et Al Frost bought 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 19th. The stock was acquired at an average price of $6.01 per share, for a total transaction of $90,150.00. Following the transaction, the chief executive officer now owns 3,068,951 shares in the company, valued at $18,444,395.51. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 1,052,238 shares of company stock worth $4,374,796. Corporate insiders own 40.19% of the company’s stock.

Several research analysts recently commented on OPK shares. Zacks Investment Research raised shares of Opko Health from a “sell” rating to a “hold” rating in a report on Thursday, October 26th. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Opko Health in a report on Monday, September 25th. BidaskClub raised shares of Opko Health from a “sell” rating to a “hold” rating in a report on Saturday, September 23rd. J P Morgan Chase & Co downgraded shares of Opko Health from an “overweight” rating to a “neutral” rating and cut their price target for the company from $12.00 to $7.00 in a report on Thursday, September 14th. Finally, Cantor Fitzgerald set a $20.00 price target on shares of Opko Health and gave the company a “buy” rating in a report on Wednesday, October 25th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $13.97.

Shares of Opko Health Inc. (OPK) opened at $5.25 on Monday. The company has a current ratio of 1.66, a quick ratio of 1.48 and a debt-to-equity ratio of 0.01. Opko Health Inc. has a 52-week low of $4.50 and a 52-week high of $12.15.

Opko Health (NASDAQ:OPK) last posted its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.03). The company had revenue of $263.50 million for the quarter, compared to analysts’ expectations of $319.43 million. Opko Health had a negative net margin of 9.45% and a negative return on equity of 5.17%. The business’s quarterly revenue was down 11.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.03) EPS. equities analysts forecast that Opko Health Inc. will post -0.27 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.watchlistnews.com/jane-street-group-llc-trims-stake-in-opko-health-inc-opk/1757065.html.

Opko Health Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Institutional Ownership by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.